Idris Ghassan, Galland Barbara, Robertson Christopher J, Farella Mauro
Craniofacial Biology and Clinical Oral Physiology Research Programme, Sir John Walsh Research Institute, University of Otago Dunedin, New Zealand.
Department of Women's and Children's Health, University of Otago Dunedin, New Zealand.
Front Physiol. 2016 Aug 19;7:353. doi: 10.3389/fphys.2016.00353. eCollection 2016.
Sleep-Disordered Breathing (SDB) varies from habitual snoring to partial or complete obstruction of the upper airway and can be found in up to 10% of children. SDB can significantly affect children's wellbeing, as it can cause growth disorders, educational and behavioral problems, and even life-threatening conditions, such as cardiorespiratory failure. Adenotonsillectomy represents the primary treatment for pediatric SDB where adeno-tonsillar hypertrophy is indicated. For those with craniofacial anomalies, or for whom adenotonsillectomy or other treatment modalities have failed, or surgery is contra-indicated, mandibular advancement splints (MAS) may represent a viable treatment option. Whilst the efficacy of these appliances has been consistently demonstrated in adults, there is little information about their effectiveness in children.
To determine the efficacy of mandibular advancement appliances for the management of SDB and related health problems in children.
METHODS/DESIGN: The study will be designed as a single-blind crossover randomized controlled trial with administration of both an "Active MAS" (Twin-block) and a "Sham MAS." Eligible participants will be children aged 8-12 years whose parents report they snore ≥3 nights per week. Sixteen children will enter the full study after confirming other inclusion criteria, particularly Skeletal class I or class II confirmed by lateral cephalometric radiograph. Each child will be randomly assigned to either a treatment sequence starting with the Active or the Sham MAS. Participants will wear the appliances for 3 weeks separated by a 2-week washout period. For each participant, home-based polysomnographic data will be collected four times; once before and once after each treatment period. The Apnea Hypopnea Index (AHI) will represent the main outcome variable. Secondary outcomes will include, snoring frequency, masseter muscle activity, sleep symptoms, quality of life, daytime sleepiness, children behavior, and nocturnal enuresis. In addition, blood samples will be collected to assess growth hormone changes.
This study was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR): [ACTRN12614001013651].
睡眠呼吸障碍(SDB)范围从习惯性打鼾到上气道部分或完全阻塞,在高达10%的儿童中存在。SDB会显著影响儿童的健康,因为它可导致生长障碍、教育和行为问题,甚至危及生命的情况,如心肺衰竭。腺样体扁桃体切除术是有腺样体扁桃体肥大指征的小儿SDB的主要治疗方法。对于患有颅面畸形的患者,或腺样体扁桃体切除术或其他治疗方式失败,或手术禁忌的患者,下颌前移矫治器(MAS)可能是一种可行的治疗选择。虽然这些矫治器在成人中的疗效已得到持续证实,但关于其在儿童中的有效性的信息却很少。
确定下颌前移矫治器对儿童SDB及相关健康问题的治疗效果。
方法/设计:本研究将设计为单盲交叉随机对照试验,使用“活性MAS”(双阻板矫治器)和“假MAS”。符合条件的参与者将是8至12岁的儿童,其父母报告他们每周打鼾≥3晚。在确认其他纳入标准后,16名儿童将进入完整研究,特别是通过头颅侧位X线片确认的骨骼I类或II类。每个孩子将被随机分配到以活性或假MAS开始的治疗序列。参与者将佩戴矫治器3周,中间间隔2周的洗脱期。对于每个参与者,将在家中收集4次多导睡眠图数据;每个治疗期前后各一次。呼吸暂停低通气指数(AHI)将作为主要结局变量。次要结局将包括打鼾频率、咬肌活动、睡眠症状、生活质量、日间嗜睡、儿童行为和夜间遗尿。此外,将采集血样以评估生长激素变化。
本研究已在澳大利亚新西兰临床试验注册中心(ANZCTR)注册:[ACTRN12614001013651]